Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Autor: Kosiborod MN; Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: mkosiborod@saint-lukes.org., Platz E; Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA., Wharton S; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., le Roux CW; St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland., Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim, Germany; 1st Department of Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany., Ajaz Hussain S; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Unseld A; Boehringer Ingelheim Pharma GmbH and Co KG, Biberach/Riss, Germany., Startseva E; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Kaplan LM; Section of Obesity Medicine and Center for Digestive Health, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.

Publikováno v: JACC. Heart failure [JACC Heart Fail] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.